Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 3 | Cell & Bioscience

Fig. 3

From: TOPBP1 as a potential predictive biomarker for enhanced combinatorial efficacy of olaparib and AZD6738 in PDAC

Fig. 3

The influential role of TOPBP1, ATR, ATM, and DDR pathways in the inhibitory effect of olaparib on pancreatic cell proliferation. A Heat map of the differential TOPBP1, ATR, and ATM gene expression in four groups based on BRCA1 mutation status and PARP sensitivity: NOBRinse (BRCA1 non-mutation and PARP insensitivity), BRinse (BRCA1 mutation and PARP insensitivity), NOBRse (BRCA1 non-mutation and PARP sensitivity), and BRse (BRCA1 mutation and PARP sensitivity). B Volcano plots illustrating the increased expression of TOPBP1 and ATR in comparison to the BRCA1 non-mutation and PARP-sensitivity groups, as well as the BRCA1 non-mutation and PARP-insensitivity groups. C Determination of PDAC cell line sensitivity to olaparib using the CCK8 assay. D Heatmap showing differences in signaling pathway enrichment alterations induced by olaparib among BXPC3 and Patu8988 cells treated with olaparib based on Gene Ontology (GO) Biological Processes (BP). E Heatmap showing differential gene expression in BXPC3 and Patu8988 cells under olaparib treatment. F Differential changes in TOPBP1 and other DDR genes analyzed by western blot and ImageJ in PDAC cell lines treated with olaparib and expressing different levels of TOPBP1

Back to article page

Cell & Bioscience

ISSN: 2045-3701

Contact us